ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.
Tag Archive for: Zynlonta
While six of the fatalities were deemed “unlikely or unrelated to the study drug,” the company nevertheless elected to suspend the entry of patients into the study.
The move comes after a review of data of 40 patients in the trial indicated potentially excessive respiratory-related events, including seven deaths and five serious adverse events.